Cargando…

Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects

OBJECTIVE: To investigate the pharmacokinetics (PK) of Morphine ARER, an extended-release (ER), abuse-deterrent formulation of morphine sulfate after oral and intranasal administration. METHODS: This randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study assessed the PK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webster, Lynn R., Pantaleon, Carmela, Iverson, Matthew, Smith, Michael D., Kinzler, Eric R., Aigner, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937443/ https://www.ncbi.nlm.nih.gov/pubmed/29849845 http://dx.doi.org/10.1155/2018/7276021

Ejemplares similares

A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine
por: Kinzler, Eric R., et al.
Publicado: (2019)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2012)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
por: Göhler, Karin, et al.
Publicado: (2019)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

An overview of abuse-deterrent opioids and recommendations for practical patient care
por: Adler, Jeremy A, et al.
Publicado: (2018)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology
por: Dasgupta, Nabarun, et al.
Publicado: (2021)

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users
por: Webster, Lynn R, et al.
Publicado: (2012)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance
por: Zhao, Liang, et al.
Publicado: (2021)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Can abuse deterrent formulations make a difference? Expectation and speculation
por: Budman, Simon H, et al.
Publicado: (2009)

US study of gliding in nondependent lung regions: the dark side of the moon
por: De Blasio, E, et al.
Publicado: (2014)

Alveolar instability caused by mechanical ventilation initially damages the nondependent normal lung
por: Pavone, Lucio, et al.
Publicado: (2007)

Differentiation of acid-ph-dependent and -nondependent entry pathways for mouse hepatitis virus
por: Kooi, Cora, et al.
Publicado: (1991)

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
por: L. Keast, Shellie, et al.
Publicado: (2016)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design
por: Joshi, Yogesh, et al.
Publicado: (2018)

Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users
por: Raofi, Saeid, et al.
Publicado: (2021)

How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era
por: Green, Traci C, et al.
Publicado: (2015)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Bed bug deterrence
por: Haynes, Kenneth F, et al.
Publicado: (2010)

Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis
por: Phung, Huyen Thi, et al.
Publicado: (2022)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Deterrents and reinforcement : the psychology of insufficient reward /
por: Lawrence, Douglas H.
Publicado: (1962)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
por: Janoff, Shannon L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dggiiandr4s4gmq98rukma1qrj